...
首页> 外文期刊>The Mount Sinai journal of medicine >Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies.
【24h】

Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies.

机译:多发性硬化症的神经治疗:新型药物和新兴治疗策略。

获取原文
获取原文并翻译 | 示例

摘要

New insights into the complex immunopathogenesis of multiple sclerosis have led to a proliferation of promising new therapeutic strategies. While the current armamentarium of immunomodulatory medications has demonstrated beneficial effects on the disease, more effective and tolerable therapies are needed. Several novel therapeutic strategies under investigation include oral therapies, monoclonal antibodies, symptomatic treatments, insights into neuroprotection and repair as well as combination regimens. New therapies may prove more efficacious and tolerable than the available arsenal of treatments; however, decisions regarding first-line therapies will expectedly become more complicated, with greater influence if risk-to-benefit ratios in light of premature safety data. Biomarker profiles may help elucidate disease subtypes as well as therapeutic response in an effort to individualize treatment choice. This review will highlight recent promising therapeutic strategies under investigation in the field of MS.
机译:对多发性硬化症的复杂免疫发病机制的新见解导致了有希望的新治疗策略的激增。尽管目前的免疫调节药物装备库已证明对该疾病具有有益作用,但仍需要更有效和可耐受的疗法。正在研究的几种新的治疗策略包括口服治疗,单克隆抗体,对症治疗,对神经保护和修复的见识以及联合用药方案。新疗法可能比现有的治疗手段更有效,更耐受。但是,如果根据过早的安全性数据得出风险收益比,则有关一线疗法的决策预计将变得更加复杂,影响更大。生物标记物谱可以帮助阐明疾病亚型以及治疗反应,以努力使治疗选择个性化。这篇综述将重点介绍MS领域正在研究的近期有希望的治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号